Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Sponsor: Neurocrine Biosciences
Summary
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).
Official title: A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
Key Details
Gender
All
Age Range
0 Years - 23 Months
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2025-09-30
Completion Date
2029-10-04
Last Updated
2026-03-20
Healthy Volunteers
No
Conditions
Interventions
Crinecerfont
Oral solution
Locations (3)
Neurocrine Clinical Site
Berlin, Germany
Neurocrine Clinical Site
Düsseldorf, Germany
Neurocrine Clinical Site
Heidelberg, Germany